234 related articles for article (PubMed ID: 10331183)
1. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
2. Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+ T Cell Function and Anti-tumor Immunity.
Shen S; Sckisel G; Sahoo A; Lalani A; Otter DD; Pearson J; DeVoss J; Cheng J; Casey SC; Case R; Yang M; Low R; Daris M; Fan B; Agrawal NJ; Ali K
Front Immunol; 2020; 11():832. PubMed ID: 32457754
[TBL] [Abstract][Full Text] [Related]
3. Facts and Hopes on Chimeric Cytokine Agents for Cancer Immunotherapy.
Ren Z; Zhang X; Fu YX
Clin Cancer Res; 2024 May; 30(10):2025-2038. PubMed ID: 38190116
[TBL] [Abstract][Full Text] [Related]
4. Long-term immunity elicited by antibody-cytokine fusion proteins protects against sequential challenge with murine mammary and colon malignancies.
Helguera G; Rodríguez JA; Daniels TR; Penichet ML
Cancer Immunol Immunother; 2007 Sep; 56(9):1507-12. PubMed ID: 17310381
[TBL] [Abstract][Full Text] [Related]
5. Antibody-cytokine fusion proteins: applications in cancer therapy.
Ortiz-Sánchez E; Helguera G; Daniels TR; Penichet ML
Expert Opin Biol Ther; 2008 May; 8(5):609-32. PubMed ID: 18407765
[TBL] [Abstract][Full Text] [Related]
6. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
De Luca R; Soltermann A; Pretto F; Pemberton-Ross C; Pellegrini G; Wulhfard S; Neri D
Mol Cancer Ther; 2017 Nov; 16(11):2442-2451. PubMed ID: 28716814
[TBL] [Abstract][Full Text] [Related]
7. Armed antibodies for cancer treatment: a promising tool in a changing era.
Danielli R; Patuzzo R; Ruffini PA; Maurichi A; Giovannoni L; Elia G; Neri D; Santinami M
Cancer Immunol Immunother; 2015 Jan; 64(1):113-21. PubMed ID: 25314912
[TBL] [Abstract][Full Text] [Related]
8. huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models.
Lo KM; Lan Y; Lauder S; Zhang J; Brunkhorst B; Qin G; Verma R; Courtenay-Luck N; Gillies SD
Cancer Immunol Immunother; 2007 Apr; 56(4):447-57. PubMed ID: 16874486
[TBL] [Abstract][Full Text] [Related]
9. Advances in engineering and delivery strategies for cytokine immunotherapy.
Bohmer M; Xue Y; Jankovic K; Dong Y
Expert Opin Drug Deliv; 2023 May; 20(5):579-595. PubMed ID: 37104673
[TBL] [Abstract][Full Text] [Related]
10. KERS-Inspired Nanostructured Mineral Coatings Boost IFN-γ mRNA Therapeutic Index for Antitumor Immunotherapy.
Shao Z; Chen L; Zhang Z; Wu Y; Mou H; Jin X; Teng W; Wang F; Yang Y; Zhou H; Xue Y; Eloy Y; Yao M; Zhao S; Cui W; Yu X; Ye Z
Adv Mater; 2023 Dec; 35(51):e2304296. PubMed ID: 37587307
[TBL] [Abstract][Full Text] [Related]
11. Cytokine/Antibody Fusion Protein Design and Evaluation.
Fabilane CS; Stephenson AC; Leonard EK; VanDyke D; Spangler JB
Curr Protoc; 2024 May; 4(5):e1061. PubMed ID: 38775006
[TBL] [Abstract][Full Text] [Related]
12. Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins.
Venetz D; Koovely D; Weder B; Neri D
J Biol Chem; 2016 Aug; 291(35):18139-47. PubMed ID: 27402834
[TBL] [Abstract][Full Text] [Related]
13. A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy.
Quijano-Rubio A; Bhuiyan AM; Yang H; Leung I; Bello E; Ali LR; Zhangxu K; Perkins J; Chun JH; Wang W; Lajoie MJ; Ravichandran R; Kuo YH; Dougan SK; Riddell SR; Spangler JB; Dougan M; Silva DA; Baker D
Nat Biotechnol; 2023 Apr; 41(4):532-540. PubMed ID: 36316485
[TBL] [Abstract][Full Text] [Related]
14. A novel strategy to generate immunocytokines with activity-on-demand using small molecule inhibitors.
Rotta G; Gilardoni E; Ravazza D; Mock J; Seehusen F; Elsayed A; Puca E; De Luca R; Pellegrino C; Look T; Weiss T; Manz MG; Halin C; Neri D; Dakhel Plaza S
EMBO Mol Med; 2024 Apr; 16(4):904-926. PubMed ID: 38448543
[TBL] [Abstract][Full Text] [Related]
15. Targeted chain-exchange-mediated reconstitution of a split type-I cytokine for conditional immunotherapy.
Vasic V; Buldun C; Ritz M; Dickopf S; Georges GJ; Spick C; Peuker A; Meier T; Mayer K; Brinkmann U
MAbs; 2023; 15(1):2245111. PubMed ID: 37608616
[TBL] [Abstract][Full Text] [Related]
16. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors.
Nash AM; Jarvis MI; Aghlara-Fotovat S; Mukherjee S; Hernandez A; Hecht AD; Rios PD; Ghani S; Joshi I; Isa D; Cui Y; Nouraein S; Lee JZ; Xu C; Zhang DY; Sheth RA; Peng W; Oberholzer J; Igoshin OA; Jazaeri AA; Veiseh O
Sci Adv; 2022 Mar; 8(9):eabm1032. PubMed ID: 35235346
[TBL] [Abstract][Full Text] [Related]
17. Harnessing cytokines and chemokines for cancer therapy.
Propper DJ; Balkwill FR
Nat Rev Clin Oncol; 2022 Apr; 19(4):237-253. PubMed ID: 34997230
[TBL] [Abstract][Full Text] [Related]
18. Spatiotemporal control of engineered bacteria to express interferon-γ by focused ultrasound for tumor immunotherapy.
Chen Y; Du M; Yuan Z; Chen Z; Yan F
Nat Commun; 2022 Aug; 13(1):4468. PubMed ID: 35918309
[TBL] [Abstract][Full Text] [Related]
19. Cytokine combinations in immunotherapy for solid tumors: a review.
Heaton KM; Grimm EA
Cancer Immunol Immunother; 1993 Sep; 37(4):213-9. PubMed ID: 8348559
[TBL] [Abstract][Full Text] [Related]
20. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity.
Leonard EK; Tomala J; Gould JR; Leff MI; Lin JX; Li P; Porter MJ; Johansen ER; Thompson L; Cao SD; Henclova T; Huliciak M; Vaněk O; Kovar M; Leonard WJ; Spangler JB
bioRxiv; 2023 May; ():. PubMed ID: 37205604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
